Neurobiochemical Markers of Brain Damage in Cerebrospinal Fluid of Acute Ischemic Stroke Patients (original) (raw)
Related papers
Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke
Journal of central nervous system disease, 2014
Cerebral ischemia promotes morphological reactions of the neurons, astrocytes, oligodendrocytes, and microglia in experimental studies. Our aim was to examine the profile of CSF (cerebrospinal fluid) biomarkers and their relation to stroke severity and degree of white matter lesions (WML). A total of 20 patients (mean age 76 years) were included within 5-10 days after acute ischemic stroke (AIS) onset. Stroke severity was assessed using NIHSS (National Institute of Health stroke scale). The age-related white matter changes (ARWMC) scale was used to evaluate the extent of WML on CT-scans. The concentrations of specific CSF biomarkers were analyzed. Patients with AIS had significantly higher levels of NFL (neurofilament, light), T-tau, myelin basic protein (MBP), YKL-40, and glial fibrillary acidic protein (GFAP) compared with controls; T-Tau, MBP, GFAP, and YKL-40 correlated with clinical stroke severity, whereas NFL correlated with severity of WML (tested by Mann-Whitney test). Seve...
Clinical Chemistry and Laboratory Medicine, 2009
Background: Neuron-specific enolase (NSE) and S100 protein are implicated in several brain injuries, including stroke. Our objective was to analyze the temporal profile and the clinical significance of NSE and S-100 in acute ischemic (IS) and intracerebral hemorrhage (ICH). Methods: We studied 224 patients with IS and 44 patients with ICH. Computerized tomography (CT) scans were performed to assess infarct volume. Stroke severity was evaluated using the National Institute of Health Stroke Scale (NIHSS), and functional outcome at 3 months with the modified Rankin Scale (mRS). Serum NSE and S100 protein were measured using an electrochemiluminescenceimmunoassay. Results: Peak values were found at 72 h for NSE and at 24 h for S100 in IS. For ICH, peak values were found at 24 h for both NSE and S100. At these time intervals S100 and NSE correlated with the NIHSS score and were independently associated with poor outcome. Conclusions: High serum NSE and S100 are associated with poor outcome in IS, and high serum NSE is associated with poor outcome in ICH. These findings suggest the potential utility of NSE and S100 as prognostic markers for acute stroke. Clin Chem Lab Med 2009;47:1513-8.
Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients
Clinical Biochemistry, 2012
Objective: To explore the value of blood markers for brain injury as outcome predictors in acute stroke. Design and methods: The study included 61 patients with acute stroke (44 ischemic and 17 hemorrhagic) and a high risk control group (79 individuals with no known history of neurological disease). Serum neuron specific enolase (NSE) and S100B were determined by immunoassay (CanAg Diagnostics, Sweden). Outcome at 60 days was evaluated with clinical scales. Results: Higher concentrations of NSE and S100B were measured in patients compared to high risk controls, but they were not related to stroke severity on admission. NSE was associated with functional neurological outcome at 60 days and to the degree of recovery, whereas S100B exhibited a strong correlation with depression symptoms at 60 days. Conclusions: The measurements of serum concentrations of NSE and S100B after acute stroke may be clinically relevant for predicting functional neurological outcome and post-stroke depression, respectively.
Journal of Clinical Neuroscience, 2005
Our goal was to determine the neuron-specific enolase (NSE) concentration in cerebrospinal fluid (CSF) and plasma in patients with the acute brain infarction (BI) and analyze the correlation between the measured NSE concentration and infarct volume and the degree of neurological and functional deficit. The study included 55 patients aged 56-68 with BI in the acute phase. The control group consisted of 16 patients subjected to diagnostic radiculography. The results showed a significant increase of NSE concentration within the first seven days in patients compared to the controls (2.838 +/- 0.504 ng/ml CSF and 4.479 +/- 0.893 ng/ml plasma). A significant correlation was found between NSE concentration and infarction volume and the degree of neurological and functional deficit both in the CSF (r = 0.828, r = 0.735, r = 0.796; p < 0.001) and in plasma (r = 0.810, r = 0.681, r = 0.783; p < 0.001). The results suggest that an early determination of this marker in CSF and plasma in patients with BI could be a valuable diagnostic factor.
International Journal of Biomedical Research, 2015
Objectives: The aim of this study is to see the role of serum NSE (Neuron Specific Enolase) as a neuronal damage marker and in differentiating the side of brain lesion in acute ischemic stroke patients. Methods: A total of 35 acute ischemic stroke patients (clinically and radiologically confirmed) irrespective of age and sex, admitted in Emergency Unit, Medicine Department within 24 hours of stroke onset were included in this study. Plain CT scan or MRI brain was done for all these patients on admission and after 48 hours to confirm the diagnosis and the side of the lesion in brain. Serum NSE was estimated by using NSE Human ELISA Kit, in the Department of Physiology. Results: In this study, serum NSE bears a positive significant correlation to the infarct volume in brain (r=0.783, p<0.001) and to the National Institute of Health Stroke Scale (NIHSS) (r=0.538, p=0.001). However, there is no significance difference between the serum NSE in right hemispheric brain lesion compared to left hemispheric brain lesion (p=0.596). Conclusions: Serum NSE within 24 hours of stroke onset can reflect the volume of brain lesion and severity of acute stroke but cannot differentiate the side of brain lesion in these patients.
2021
Introduction: Acute ischaemic infarction is the third etiology of death and first etiology of disability across the globe. Cerebrovascular accident is an emergency condition requiring immediate intervention. The blood brain barrier compromised in patients with acute ischaemic stroke, leakage of neuro-biochemical protein markers like NSE into the peripherial circulation allow pathogenesis and prognostication of patient‘s with CVA to be weighed up additionally. The current work structured to determine the marker of brain damage, NSE in serum of patient‘s with acute ischaemic infarction as a diagnostic and/or monitoring tool for early prognosis of ischaemic stroke. Objectives: Study of neuron-specific enolase as potential biomarker for assessing the severityand outcome in patients with acute ischaemic stroke. Materials and Methods: The material for the present study will be collected from patients who attend the Outpatient department and Inpatient department in BLDEU‘S Shri. B.M.Patil ...
Journal of Academic Emergency Medicine, 2014
Objective: Use of biochemical markers of cerebral ischemia is a newly favored approach for early diagnosis of ischemic stroke. Our aim was to establish the sensitivity and specificity of ischemia-modified albumin (IMA) in acute ischemic stroke and to compare it with S100b and neuron-specific enolase (NSE). We also intended to investigate the usefulness of a panel composed of these three biomarkers in acute ischemic stroke.
Myelin Basic Protein and Ischemia Modified Albumin Levels in Acute Ischemic Stroke Cases
Pakistan Journal of Medical Sciences, 2015
Objective: To investigate early diagnostic effects of serum myelin basic protein (MBP) and ischemic modified albumin (IMA) levels in patients with ischemic stroke. Methods: Fifty patients who presented to an emergency service with acute ischemic stroke between June 2013 to March 2014 were evaluated with the National Institute of Health Stroke Scale (NIHSS) and diffusion-weighted magnetic resonance imaging (MRI). Thirty four healthy cases were included as control group. All patients' serum IMA and MBP level were assessed. Results: Mean IMA value was 0.52±0.25 cases with acute ischemic stroke and serum IMA levels were significantly higher than the control group (p<0.01). No statistical significance was observed between acute ischemic stroke group and control group related to the MBP serum levels (P>0.05). Statistically significant correlation was detected between the volumes of diffusion restriction on MRI and NIHSS score (P=0.002,r=0.43) and IMA (P=0.015,r=0.344) levels. Conclusions: We have found that serum IMA levels are elevated in acute ischemic stroke cases and these levels are correlated with the ischemic tissue volume. MBP levels do not increase in early period of stroke cases.